Design, synthesis and molecular docking of novel triazole derivatives as potential CoV helicase inhibitors

1. R. L. Graham, E. F. Donaldson and R. S. Baric, A decade after SARS: strategies for controlling emerging coronaviruses, Nat. Rev. Microbiol. 11 (2013) 836–848; https://doi.org/10.1038/nrmicro314310.1038/nrmicro3143514754324217413Search in Google Scholar

2. V. S. Raj, H. Mou, S. L. Smits, D. H. Dekkers, M. A. Müller, R. Dijkman, D. Muth, J. A. Demmers, A. Zaki, R. A. Fouchier, V. Thiel, C. Drosten, P. J. Rottier, A. D. Osterhaus, B. J. Bosch and B. L. Haagmans, Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC, Nature495 (2013) 251–254; https://doi.org/10.1038/nature1200510.1038/nature12005709532623486063Search in Google Scholar

3. A. M. Zaki, S. V. Boheemen, T. M. Bestebroer, A. D. Osterhaus and R. A. Fouchier, Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia, N. Engl. J. Med.367 (2012) 1814–1820; https://doi.org/10.1056/NEJMoa121172110.1056/NEJMoa121172123075143Search in Google Scholar

4. P. A. Rota, M. S. Oberste, S. S. Monroe, W. A. Nix, R. Campagnoli, J. P. Icenogle, S. Peñaranda, B. Bankamp, K. Maher, M. H. Chen, S. Tong, A. Tamin, L. Lowe, M. Frace, J. L. DeRisi, Q. Chen, D. Wang, D. D. Erdman, T. C. Peret, C. Burns, T. G. Ksiazek, P. E. Rollin, A. Sanchez, S. Liffick, B. Holloway, J. Limor, K. McCaustland, M. Olsen-Rasmussen, R. Fouchier, S. Günther, A. D. Osterhaus, C. Drosten, M. A. Pallansch, L. J. Andersonthe and W. J. Bellini, Characterization of a novel coronavirus associated with severe acute respiratory syndrome, Science300 (2003) 1394–1399; https://doi.org/10.1126/science.108595210.1126/science.108595212730500Search in Google Scholar

5. J. S. M. Peiris, K. Y. Yuen, A. D. M. E. Osterhaus and K. Stöhr, The severe acute respiratory syndrome, N. Engl. J. Med.349 (2003) 2431–2441; https://doi.org/10.1056/NEJMra03249810.1056/NEJMra03249814681510Search in Google Scholar

6. P. M. Penttinen, K. Kaasik-Aaslav, A. Friaux, A. Donachie, B. Sudre, A. J. Amato-Gauci, Z. A. Memish and D. Coulombier, Taking stock of the first 133 MER S coronavirus cases globally – Is the epidemic changing? Euro Surveill. 18 (2013) 1–5; https://doi.org/10.2807/1560-7917.ES2013.18.39.2059610.2807/1560-7917.ES2013.18.39.2059624094061Search in Google Scholar

7. World Health Organization, MERS-CoV Global Summary and Assessment of Risk, (WHO/MERS/RA/August18), WHO, Geneva 2018Search in Google Scholar

8. A. O. Adedeji and S. G. Sarafianos, Antiviral drugs specific for coronaviruses in preclinical development, Curr. Opin. Virol.8 (2014) 45–53; https://doi.org/10.1016/j.coviro.2014.06.00210.1016/j.coviro.2014.06.002419580424997250Search in Google Scholar

9. L. J. Stockman, R. Bellamy and P. Garner, SARS: Systematic review of treatment effects, PLoS Med. 3 (2006) 1525–1531; https://doi.org/10.1371/journal.pmed.003034310.1371/journal.pmed.0030343156416616968120Search in Google Scholar

10. R. Y. Kao, W. H. Tsui, T. S. Lee, J. A. Tanner, R. M. Watt, J. D. Huang, L. Hu, G. Chen, Z. Chen, L. Zhang, T. He, K. H. Chan, H. Tse, A. P. To, L. W. Ng, B. C. Wong, H. W. Tsoi, D. Yang, D. D. Ho and K. Y. Yuen, Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics, Chem. Biol. 11 (2004) 1293–1299; https://doi.org/10.1016/j.chembiol.2004.07.01310.1016/j.chembiol.2004.07.013712855315380189Search in Google Scholar

11. D. N. Frick and A. M. I. Lam, Understanding helicases as a means of virus control, Curr. Pharm. Des. 12 (2006) 1315–1338; https://doi.org/10.2174/13816120677636114710.2174/138161206776361147357168616611118Search in Google Scholar

12. W. Hao, J. A. Wojdyla, R. Zhao, R. Han, R. Das, I. Zlatev, M. Manoharan, M. Wang and S. Cui, Crystal structure of Middle East respiratory syndrome coronavirus helicase, PLoS Pathog. 13 (2017) e1006474 (19 pages); https://doi.org/10.1371/j.ppat.100647410.1371/journal.ppat.1006474Search in Google Scholar

13. A. O. Adedeji and H. Lazarus, Biochemical characterization of Middle East respiratory syndrome coronavirus helicase, mSphere1 (2016) e00235-16 (14 pages); https://doi.org/org/10.1128/mSphere.00235-1610.1128/mSphere.00235-16Search in Google Scholar

14. D. Dheer, V. Singh and R. Shankar, Medicinal attributes of 1,2,3-triazoles: Current developments, Bioorg. Chem. 71 (2017) 30–54; https://doi.org/10.1016/j.bioorg.2017.01.01010.1016/j.bioorg.2017.01.01028126288Search in Google Scholar

15. Y. W. He, C. Z. Dong, J. Y. Zhao, L. Ma, Y. H. Li and H. A. Aisa, 1,2,3-Triazole-containing derivatives of rupestonic acid: Click-chemical synthesis and antiviral activities against influenza viruses, Eur. J. Med. Chem. 76 (2014) 245–255; https://doi.org/10.1016/j.ejmech.2014.02.02910.1016/j.ejmech.2014.02.02924583605Search in Google Scholar

16. J. Zhao and H. A. Aisa, Synthesis and anti-influenza activity of aminoalkyl rupestonates, Bioorg. Med. Chem. Lett.22 (2012) 2321–2325; https://doi.org/10.1016/j.bmcl.2012.01.05610.1016/j.bmcl.2012.01.05622341943Search in Google Scholar

17. A. O. Adedeji, K. Singh, N. E. Calcaterra, M. L. DeDiego, L. Enjuanes, S. Weiss and S. G. Sarafianos, Antimicrob. Agents Chemother.56 (2012) 4718–4728; https://doi.org/10.1128/AAC.00957-1210.1128/AAC.00957-12342189022733076Search in Google Scholar

18. A. O. Adedeji, K. Singh, A. Kassim, C. M. Coleman, R. Elliott, S. R. Weiss, M. B. Frieman and S. G. Sarafianos, Evaluation of SSYA10-001 as a replication inhibitor of SARS, MHV and MERS corona-viruses, Antimicrob. Agents Chemother. 58 (2014) 4894–898; https://doi.org/10.1128/AAC.02994-1410.1128/AAC.02994-14413604124841268Search in Google Scholar

19. A. A. Fadda, S. Bondock, R. Rabie and H. A. Etman, Cyanoacetamide derivatives as synthons in heterocyclic synthesis, Turk. J. Chem.32 (2008) 259–286; https://doi.org/10.1.1.574.4827Search in Google Scholar

20. J. A. Tanner, R. M. Watt, Y. B. Chai, L. Y. Lu, M. C. Lin, J. S. Peiris, L. L. Poon, H. F. Kung and J. D. Huang, The severe acute respiratory syndrome (SARS) coronavirus NTPase/helicase belongs to a distinct class of 5’ to 3’ viral helicases, J. Biol. Chem. 278 (2003) 39578–39582; https://doi.org/10.1074/jbc.C30032820010.1074/jbc.C300328200806095012917423Search in Google Scholar

21. D. J. T. Porter, Inhibition of the hepatitis C virus helicase-associated ATPase activity by the combination of ADP, NaF, MgCl₂, and poly(rU) – Two ADP binding sites on the enzyme-nucleic acid complex, J. Biol. Chem. 273 (1998) 7390–7396; https://doi.org/10.1074/jbc.273.13.739010.1074/jbc.273.13.73909516436Search in Google Scholar

22. A. M. Boguszewska-Chachulska, M. Krawczyk, A. Stankiewicz, A. Gozdek, A-L. Haenni and L. Strokovskaya, Direct fluorometric measurement of hepatitis C virus helicase activity, FEBS Lett.567 (2004) 253–258; https://doi.org/10.1016/j.febslet.2004.04.07210.1016/j.febslet.2004.04.07215178332Search in Google Scholar

23. M. K. Abdel-Hamid, A. A. Abdel-Hafez, N. A. El-Koussi, N. M. Mahfouz, A. Innocenti and C. T. Supuran, Design, synthesis, and docking studies of new 1,3,4-thiadiazole-2-thione derivatives with carbonic anhydrase inhibitory activity, Bioorg. Med. Chem. 15 (2007) 6975–6984; https://doi.org/10.1016/j.bmc.2007.07.04410.1016/j.bmc.2007.07.04417822907Search in Google Scholar

24. J. A. Tanner, B. J. Zheng, J. Zhou, R. M. Watt, J. Q. Jiang, K. L. Wong, Y. P. Lin, L.Y. Lu, M. L. He, H. F. Kung, A. J. Kesel and J. D. Huang, The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus, Chem. Biol. 12 (2005) 303–311; https://doi.org/10.1016/j.chembiol.2005.01.00610.1016/j.chembiol.2005.01.006711098815797214Search in Google Scholar

25. Z-Y. Wu, N. Liu, B. Qin, L. Huang, F. Yu, K. Qian, S. L. Morris-Natschke, S. Jiang, C. H. Chen, K-H. Lee and L. Xie, Optimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS, ChemMedChem9 (2014) 1546–1555; https://doi.org/10.1002/cmdc.20140007510.1002/cmdc.201400075408599624895029Search in Google Scholar